Article Details

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of ...

Retrieved on: 2023-09-14 15:03:33

Tags for this article:

Click the tags to see associated articles and topics

Q32 Bio and Horizon Therapeutics plc Announce Dosing of First Patient in Phase 2 Trial of .... View article details on hiswai:

Excerpt

“Bempikibart represents a potential unique approach to correcting immune system dysregulation in this and other diseases.” “IL-7 is involved in ...

Article found on: pipelinereview.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up